Supernus Pharmaceuticals Inc (SUPN) financials
Supernus Pharmaceuticals revenue and earnings by year
Supernus Pharmaceuticals's revenue was $719 million in the fiscal year to December 31, 2025, up 8.6% from the year before. Net income was -$38.5 million, -5.4% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 14.4% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 719 | 662 | 608 | 667 | 580 | 520 | 393 | 409 | 302 | 215 |
| Revenue growth | 8.6% | 8.9% | -8.9% | 15.1% | 11.4% | 32.5% | -3.9% | 35.3% | 40.6% | — |
| Gross profit | 644 | 584 | 524 | 580 | 505 | 468 | 376 | 394 | 287 | 203 |
| Gross margin | 89.6% | 88.2% | 86.2% | 86.9% | 87.1% | 89.9% | 95.8% | 96.2% | 95.0% | 94.4% |
| Operating income | -37 | 76 | -7 | 46 | 79 | 174 | 149 | 144 | 100 | 54 |
| Operating margin | -5.1% | 11.4% | -1.1% | 6.8% | 13.7% | 33.4% | 37.8% | 35.3% | 32.9% | 25.2% |
| Net income | -39 | 74 | 1 | 61 | 53 | 127 | 113 | 111 | 57 | 91 |
| Net margin | -5.4% | 11.2% | 0.2% | 9.1% | 9.2% | 24.4% | 28.8% | 27.1% | 19.0% | 42.4% |
| Diluted EPS | -$0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 | $2.11 | $2.06 | $1.06 | $1.70 |
| Free cash flow | 46 | 171 | 111 | 116 | 125 | 135 | 142 | 128 | 113 | 65 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open SUPN in Markets.
How Supernus Pharmaceuticals makes money
Revenue by segment in the quarter to September 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $179M | 78.7% |
| ONAPGO | $17.1M | 7.5% |
| Trokendi Xr | $10.2M | 4.5% |
| Oxtellar XR | $7.96M | 3.5% |
| Royalty License & Other Revenue | $6.50M | 2.9% |
| APOKYN | $6.49M | 2.9% |
See also: SUPN valuation and P/E history · SUPN returns
No forecast, no recommendation. This page describes Supernus Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.